Objective: To inform readers of the current and forthcoming skin barrier interventions that have clinically relevant implications in the prevention of allergic sensitization and atopic diseases. Data Sources: Peer-reviewed journal articles indexed on PubMed and clinical trials referenced on clinicaltrials. gov were analyzed. Study Selections: Literature searches from PubMed and clinicaltrials.gov were performed using combinations of the following search terms: prevention, allergy, atopy, skin, cutaneous, microbiome, microbiota, Staphylococcus aureus, atopic dermatitis, eczema, food allergy, and asthma. Results: The skin barrier represents an entry point for allergic sensitization and TH2-mediated allergic disorders. Results from clinical trials designed to improve microbiome complexity and reduce S aureus colonization, provide skin barrier enhancement, and deliver epicutaneous immunotherapy are summarized and discussed in the context of primary, secondary, and tertiary prevention of allergic disease. Conclusion: The skin barrier is a promising target for prevention of allergic disease, though clinical trial results thus far have been mixed, at best. (c) 2022 American College of Allergy, Asthma Immunology. Published by Elsevier Inc.
展开▼
机译:目的:向读者介绍当前和即将推出的皮肤屏障干预措施,这些干预措施在预防过敏致敏和特应性疾病方面具有临床相关意义。数据来源:在 PubMed 上索引的同行评审期刊文章和在临床试验中引用的临床试验。对政府进行了分析。研究选择:使用以下检索词的组合对PubMed和 clinicaltrials.gov 进行文献检索:预防、过敏、特应性、皮肤、皮肤、微生物组、微生物群、金黄色葡萄球菌、特应性皮炎、湿疹、食物过敏和哮喘。结果:皮肤屏障是过敏致敏和TH2介导的过敏性疾病的切入点。在过敏性疾病的一级、二级和三级预防的背景下,总结和讨论了旨在改善微生物组复杂性和减少金黄色葡萄球菌定植、增强皮肤屏障和提供表皮免疫治疗的临床试验结果。结论:皮肤屏障是预防过敏性疾病的一个有希望的靶点,尽管迄今为止的临床试验结果充其量是喜忧参半。(c) 2022 年美国过敏、哮喘和免疫学会。由以下开发商制作:Elsevier Inc.
展开▼